Application of gamma process to two-agent combinations with delayed toxicity
From MaRDI portal
Publication:5083969
DOI10.1080/03610918.2018.1554107zbMATH Open1489.62361OpenAlexW2914626152MaRDI QIDQ5083969FDOQ5083969
Authors: Shinjo Yada, Chikuma Hamada 
Publication date: 21 June 2022
Published in: Communications in Statistics. Simulation and Computation (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1080/03610918.2018.1554107
Recommendations
- A Bayesian dose-finding design for drug combination trials with delayed toxicities
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- A Bayesian adaptive design for addressing correlated late-onset outcomes in phase I/II randomized trials of drug combinations in oncology
- Dose-finding with two agents in phase I oncology trials
- Time-to-event continual reassessment method incorporating treatment cycle information with application to an oncology phase I trial
Cites Work
- The Calculation of Posterior Distributions by Data Augmentation
- Title not available (Why is that?)
- Bayesian biostatistics
- A Bayesian nonparametric approach to reliability
- A Bayesian dose-finding design for drug combination trials with delayed toxicities
- A Latent Contingency Table Approach to Dose Finding for Combinations of Two Agents
- Bayesian data augmentation dose finding with continual reassessment method and delayed toxicity
- Bayesian designs for phase I--II clinical trials
- Robust EM continual reassessment method in oncology dose finding
Cited In (1)
This page was built for publication: Application of gamma process to two-agent combinations with delayed toxicity
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q5083969)
